TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05994885

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root surface debridement
Description: the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
Study: NCT04957238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARBORea decision-making tool
Description: Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
Study: NCT06315465

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkin's Diet with standard of care
Description: children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
Study: NCT05586841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: 100 mg/d or 125 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide: 25 mg/BIW or 20 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
Study: NCT05819320

Intervention type: OTHER
Intervention: observe pattern of mucocutaneous manifestations in chronic kidney disease patients
Description: 1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease

Intervention type: OTHER
Intervention: observe pattern of mucocutaneous manifestations in chronic kidney disease patients
Description: 1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease

Intervention type: OTHER
Intervention: observe pattern of mucocutaneous manifestations in chronic kidney disease patients
Description: 1. To study the patterns of mucocutaneous disorders in Chronic Kidney Disease patients .~2. Comparison of the patterns of mucocutaneous manifestations and their correlation with the different stages of Chronic Kidney Disease
Study: NCT05583019

Intervention type: DEVICE
Intervention: GENEActiv Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: GENEActiv Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: GENEActiv Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: GENEActiv Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Centrepoint Insights Watch (CPIW) Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Centrepoint Insights Watch (CPIW) Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Centrepoint Insights Watch (CPIW) Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Centrepoint Insights Watch (CPIW) Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Apple Watch Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Apple Watch Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Apple Watch Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Apple Watch Accelerometry Device
Description: a watch like wearable sensor

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep monitor

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep monitor

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep monitor

Intervention type: DEVICE
Intervention: Polysomnography
Description: Sleep monitor

Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera

Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera

Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study: NCT06036420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flashed Light Therapy
Description: Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
Study: NCT05583019

Intervention type: DEVICE
Intervention: Videography
Description: Thermal Camera
Study: NCT05211817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex lifestyle intervention
Description: Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex lifestyle intervention
Description: Volunteers will undergo a 3-month comprehensive lifestyle modification, consisting of a combined aerobic-strength training intervention, nutritional and psychological counseling. Regular examinations (body weight, waist circumference, body composition by bioimpedance) will be performed every week. Probands in the intervention and control groups will have the opportunity to participate in a long-term program of physical activity at BMC SAS after the end of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: 3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: 3 months carnosine supplementation (2 g per day) will be given in parallel with a complex lifestyle modification. Carnosine is a dipeptide of beta-alanyl l-histidine, which is found in skeletal muscle and in certain areas of the brain. It is a well-tolerated and approved food supplement in Slovakia. Scientists have extensive experience with the administration of carnosine (deCourten, Ukropcová et al, Obesity 2015 https://doi.org/10.1002/oby.21434; Schon, Ukropcova et al, 2019 DOI: 10.3390 / nu11061196 and others). Carnosine has the potential to positively affect glucose metabolism, and improve the adaptive response to exercise training interventions.
Study: NCT06315465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
Study: NCT05328752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: XXB750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: XXB750

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05138887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrahydrobiopterin
Description: The experimental group1 was administered BH4 orally with a dose of 2 mg/kg.d, once per day, and the experimental group 2 was administered BH4 orally witha dose of 5 mg/kg.d, two times a day (If the drug dose is within the range of 151-250mg, the drug dose is 200mg) or three times a day (If the drug dose is within the range of 251-350mg, the drug dose is 300mg). The oral administration of pills was started on the same day of the first radiation treatment, and ended three months after the treatment ended.
Study: NCT05595772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Growth Factors (CGF)
Description: Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Growth Factors (PRGF)
Description: Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: Dental Implant surgery
Description: Immediate implant following extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: Dental Implant surgery
Description: Immediate implant following extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: A Traumatic tooth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: A Traumatic tooth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogenic bone grafting
Description: Application of bovine bone grafting over area of dehiscence around immediate implant
Study: NCT05825391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjustment of Antiplatelet Drugs
Description: The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
Study: NCT06036420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videoconference-delivered Cognitive Behavioral Therapy
Description: Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
Study: NCT06386835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Paste
Description: Collagen paste injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal advancement
Description: Mucosal advancement flap
Study: NCT05670613

Intervention type: OTHER
Group type: OTHER
Intervention: CDSS Canceling
Description: The use of Clinical Decision Support System in Parenteral Nutrition

Intervention type: OTHER
Group type: OTHER
Intervention: CDSS Canceling
Description: The use of Clinical Decision Support System in Parenteral Nutrition
Study: NCT05934877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP navigation + text messaging
Description: Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
Study: NCT05199688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
Study: NCT05784519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSCs eye drops
Description: MSCs were used to prepare single-cell suspension, and 0.9% sodium chloride was added to balance PH value to prepare the effective, safe and stable eye drops. Giving the patient with 5×10\^5 /50μl in each eye, twice a day for 2 weeks.
Study: NCT05331794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on BIOFIT-Park
Description: Participant will perform one strength training session on the new line of outdoor fitness equipment BIOFIT-Park. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on gym park equipament
Description: Participant will perform one strength training session on a gym park equipment. 6 machines will be used. The training will consist of 3 sets of 15-20 repetitions, working at 60-65% RM. The execution speed will be 1x1, the rest between machines will be 20 seconds and macropauses of 90 seconds between series.
Study: NCT05199688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
Study: NCT05975073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: Administered PO
Study: NCT04600791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BATwire Implant Kit
Description: The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
Study: NCT06004830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
Study: NCT06177106

Intervention type: OTHER
Group type: OTHER
Intervention: Solar Simulated Light
Description: Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.

Intervention type: OTHER
Group type: OTHER
Intervention: Solar Simulated Light
Description: Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
Study: NCT05205512

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Maintain current levels of physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Participate in telehealth exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Participate in telehealth exercise intervention
Study: NCT06056245

Intervention type: PROCEDURE
Intervention: Preoperative step
Description: * Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent.

Intervention type: DRUG
Intervention: Intraoperative
Description: Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
Study: NCT04786587

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study.
Study: NCT05024708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac exercises and tests
Description: Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac exercises and tests
Description: Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac exercises and tests
Description: Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac exercises and tests
Description: Rest ECG, rest echocardiography, cardio-pulmonary exercise test, exercise echocardiography, holter ECG monitor (48 yours), rest CMR, exercise CMR (ergocycle)
Study: NCT05095350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic powder
Description: Probiotic powder containing 10 strains from Lactobacillus and Bifidobacterium genus.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder containing maltodextrin and no probiotics.
Study: NCT03887221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide 50 mg
Description: Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.